SCHEMBL5598191

SCHEMBL5598191

CCOC(=O)CNC(=O)C(C(C)C)N(C(C)=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.40
ALOX15 P16050 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
ALOX12 P18054 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 2/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 4/20 0.39
IDH1 O75874 1/20 0.39
THRB P10828 1/20 0.38
F2 P00734 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29600101 1.00 NPSR1 (0.40) NPSR1ALOX15GAAMAPTALOX12
SCHEMBL5598193 1.00 NPSR1 (0.40) NPSR1ALOX15GAAMAPTALOX12
SCHEMBL18546019 0.91 NPSR1 (0.43) NPSR1GAAMAPTSMN1; SMN2POLB
SCHEMBL942690 0.87 GPR139 (0.42) NPSR1SMN1; SMN2POLBKMT2AALDH1A1
SCHEMBL29600045 0.87 GPR139 (0.42) NPSR1SMN1; SMN2POLBKMT2AALDH1A1
SCHEMBL1170578 0.87 GPR139 (0.42) NPSR1SMN1; SMN2POLBKMT2AALDH1A1
SCHEMBL15016758 0.87 ALDH1A1 (0.43) NPSR1MAPTSMN1; SMN2POLBKMT2A
SCHEMBL17860509 0.86 MAPT (0.39) GAAMAPTSMN1; SMN2POLBALDH1A1
SCHEMBL3746187 0.84 CYP3A4 (0.42) NPSR1GAAPOLBKMT2AALDH1A1
SCHEMBL17860521 0.83 PDCD1 (0.40) ALOX15GAAMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110128500-B Ugi mixed solvent process for preparing alpha-amido amides 杭州迈世腾药物科技有限公司 2020-12-22 CN claimed
CN-110128500-B Ugi mixed solvent process for preparing alpha-amido amides 杭州迈世腾药物科技有限公司 2020-12-22 CN disclosed
CN-110128500-B Ugi mixed solvent process for preparing alpha-amido amides 杭州迈世腾药物科技有限公司 2020-12-22 CN disclosed
US-7998933-B2 Process for treating the skin comprising applying to the skin at least one composition comprising at least one N-aminoacylamide L'OREAL S.A. (FR) 2011-08-16 US disclosed
US-20110021438-A1 NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING THEM AND USES THEREOF L'OREAL S.A. (FR) 2011-01-27 US disclosed
US-7838020-B2 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor L'OREAL (FR) 2010-11-23 US disclosed
US-7838020-B2 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor L'OREAL (FR) 2010-11-23 US disclosed
EP-1269990-B1 Cosmetic or dermatological composition comprising acylaminoamide derivatives OREAL (FR) 2010-10-13 EP disclosed
US-7786321-B2 Compounds of the N-acylamino amide family compositions comprising them and uses thereof L'OREAL S.A. (FR) 2010-08-31 US disclosed
US-7786321-B2 Compounds of the N-acylamino amide family compositions comprising them and uses thereof L'OREAL S.A. (FR) 2010-08-31 US disclosed
US-20080293962-A1 Novel compounds of the N-acylamino amide family compositions comprising them and uses thereof L'OREAL S.A. (FR) 2008-11-27 US disclosed
US-20080293962-A1 Novel compounds of the N-acylamino amide family compositions comprising them and uses thereof L'OREAL S.A. (FR) 2008-11-27 US disclosed
US-7419970-B2 Aging resistance; controlling skin elasticity; example: ethyl {2-[acetyl(3-trifluoromethyl-phenyl)amino]-3-methylbutyrylamino}acetate; of slowing down the degradation activity of the elastic fibres of the intercellular spaces, may make it possible to reduce this phenomenon of accelerated ageing of skin L'OREAL (FR) 2008-09-02 US disclosed
EP-1269988-B1 Cosmetic or dermatological composition comprising acylaminoamide derivatives OREAL (FR) 2007-12-05 EP disclosed
US-20070202203-A1 ANTI-AGEING COMPOSITION L'OREAL (FR) 2007-08-30 US disclosed
EP-1275372-B1 Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor OREAL (FR) 2007-06-13 EP disclosed
EP-1399113-B1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING N-ACYLAMINOAMIDE DERIVATIVES OREAL (FR) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293962-A1 Novel compounds of the N-acylamino amide family compositions comprising them and uses thereof AADAC, COL14A1, COL2A1 NPSR1 3401/4885ALOX15 1157/4885GAA 934/4885
US-20110021438-A1 NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING THEM AND USES THEREOF COL2A1, COL14A1, AADAC NPSR1 3538/4885ALOX15 1071/4885GAA 679/4885
US-20070202203-A1 ANTI-AGEING COMPOSITION GLA, CUTA, CD44 NPSR1 2258/4885ALOX15 241/4885GAA 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.